09926 康方生物
按盘价 
60.850 -1.450 (-2.327%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | 27.639% | -22.683% | -24.820% | -42.577% | -28.855% |
| 股东资金回报率 (%) | 55.358% | -40.292% | -33.858% | -74.047% | -154.249% |
| 资本运用回报率 (%) | 25.428% | -28.257% | -25.901% | -31.931% | -21.594% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 97.056% | 88.764% | 86.146% | N/A | -- |
| 未计利息、税项、折旧及摊销前利润率 (%) | 49.583% | -154.611% | -533.523% | N/A | -464.796% |
| 税前边际利润率 (%) | 42.917% | -169.785% | -557.616% | N/A | -488.796% |
| 纯利率 (%) | 44.812% | -139.484% | -476.422% | N/A | -473.181% |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 4.713 X | 2.247 X | 4.808 X | 17.658 X | 10.487 X |
| 速动比率 (X) | 4.387 X | 1.996 X | 4.508 X | 17.298 X | 10.358 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 50.782% | 53.638% | 31.743% | 10.522% | 87.106% |
| 总债项 / 总资产比率 (%) | 32.577% | 34.191% | 17.883% | 5.160% | 13.074% |
| 净债项 / 总资产比率 (%) | 15.778% | -3.881% | -37.085% | -64.455% | -57.822% |
| 总债项 / 股东资金比率 (%) | 63.740% | 71.296% | 27.162% | 6.247% | N/A |
| 长期债项 / 股东资金比率 (%) | 55.108% | 54.152% | 25.473% | 5.723% | N/A |
| 净债项 / 股东资金比率 (%) | 30.871% | -8.092% | -56.327% | -78.025% | N/A |
| 净现金 / (债项) ($) | (14.49亿) | 2.13亿 | 17.82亿 | 24.86亿 | 9.67亿 |
| 每股净现金 / (债项) ($) | (1.722) | 0.254 | 2.181 | 3.158 | -- |
| 总债项 / 资本运用比率 (%) | 37.496% | 45.446% | 20.708% | 5.398% | 14.082% |
| 利息盈利率 (X) | 23.331 X | N/A | N/A | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 1004.895日 | 1044.097日 | 1505.434日 | -- | -- |
| 应收贸易帐周转率日数 (日) | 22.846日 | 81.243日 | 164.763日 | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 26.764日 | 112.260日 | 257.963日 | N/A | 232.433日 |
| 备注： | 实时报价更新时间为20/12/2024 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
